A Study of the TheraBionic P1 Device in Breast Cancer
NCT07218432
This study is recruiting at 8 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage IIIA
- Hormone Receptor Positive Tumor
- HER2-negative Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 22 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Last updated on ClinicalTrials.gov
- April 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 8
- Karmanos Cancer Institute at McLaren Clarkston · Clarkston, MI
- Karmanos Cancer Institute · Detroit, MI
- Karmanos Cancer Institute Weisberg Cancer Treatment Center · Farmington Hills, MI
- Karmanos Cancer Institute at McLaren Flint · Flint, MI
- Karmanos Cancer Institute at McLaren Greater Lansing · Lansing, MI
- Karmanos Cancer Institute at McLaren Lapeer Region · Lapeer, MI
- Karmanos Cancer Institute at McLaren Northern Michigan · Petoskey, MI
- Karmanos Cancer Institute at McLaren Port Huron · Port Huron, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.